ArticleInternational journal of molecular sciences2026
Fluticasone Propionate/Anti-IgE Combination Preserves Bone Mechanical and Mineral Integrity Better than Monotherapies or Anti-TNF-α in Mice with Ovalbumin-Induced Allergic Airway Inflammation.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic asthma is among the type 2-driven chronic inflammatory allergic diseases. Osteoimmunological findings indicate that shared systemic immune mediators and persistent inflammation can disrupt skeletal homeostasis and promote bone fragility. Treatment commonly includes inhaled corticosteroids like fluticasone propionate (FP) to suppress inflammation, with anti-immunoglobulin E (anti-IgE) biologics added to interrupt the IgE-mediated allergic cascade. TNF-α inhibitors (anti-TNF) are also being studied for their impact on inflammatory pathways. However, their capacity to preserve bone mechanical/mineral integrity in allergic airway inflammation (AAI) remains unclear. This study compared the efficacy of anti-TNF, FP, and anti-IgE monotherapies and an FP/anti-IgE combination in mitigating AAI-induced deficits in bone mechanical/mineral integrity in an ovalbumin (OVA)-induced chronic murine AAI model. Fifty-six male BALB/c mice (8-10 weeks old; 22-24 g) were randomly assigned to control, AAI (OVA-sensitized/challenged), and five treatment cohorts: FP (2000 μg), low-/high-dose anti-IgE (aIgE-L/aIgE-H; 100/200 μg), anti-TNF (aTNF; 6.25 mg/kg-bw), and FP/aIgE-H combination. Following an 8-week protocol, three-point bending and inductively coupled plasma-mass spectrometry (ICP-MS) were used to assess bone mechanical properties and physicochemical characteristics of the mineral phase (calcium (Ca) and phosphorus (P) levels; stoichiometric Ca/P ratio), respectively. Analyses showed that aIgE-L and FP monotherapies failed to mitigate AAI-induced bone changes. aTNF and aIgE-H monotherapies provided comparable protection of cross-sectional properties, rigidity, energy-to-fracture, elastic modulus, and yield/ultimate moments; however, aIgE-H was more efficacious in preserving Ca and P levels and the stoichiometric Ca/P ratio. The FP/aIgE-H combination demonstrated the greatest efficacy in preventing mechanical deterioration and preserving mineral integrity, suggesting it as the optimal strategy for maintaining skeletal health in the management of type 2-driven AAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.